DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients
Zhaohui Ni,Renhua Lu,Xudong Xu,Xueyan Bian,Zhihong Zhou,Junwei Yang,Qun Luo,Menghua Chen,Chaosheng Chen,Xiuli Sun,Lei Yu,Qiang He,Hong Jiang,Weijie Yuan,Yi Li,Rong Zhou,Jianqin Wang,Xinzhou Zhang,Li Zuo,Xiangwen Meng,Zhiren Chang,June Zhao,Peter Wessman,Peng Xiang,DIALIZE China Study Group,Zhaohui Ni,Renhua Lu,Xudong Xu,Xueyan Bian,Zhihong Zhou,Junwei Yang,Qun Luo,Menghua Chen,Chaosheng Chen,Xiuli Sun,Lei Yu,Qiang He,Hong Jiang,Weijie Yuan,Yi Li,Rong Zhou,Jianqin Wang,Xinzhou Zhang,Li Zuo,Xiangwen Meng,Zhiren Chang,June Zhao,Peter Wessman,Peng Xiang,Jianying Niu,Tiekun Yan,Zhigang Ma,Chen Yu,Hong Cheng,Aimin Zhong,Ping Luo,Caili Wang,Pearl Pai,Zunsong Wang,Niansong Wang,Changhua Liu,Chengyun Xu,Rui Zhang,Jiaxiang Ding,Yueyi Deng,Jianrao Lu,Song Wang,Wei Ren,Haijiao Jin
DOI: https://doi.org/10.1016/j.clinthera.2023.04.014
IF: 3.637
2023-06-01
Clinical Therapeutics
Abstract:PURPOSE: The DIALIZE China study (Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects) (NCT04217590) evaluated sodium zirconium cyclosilicate (SZC) for the management of hyperkalemia in Chinese patients undergoing hemodialysis.METHODS: In the double-blind, Phase IIIb DIALIZE China study, Chinese adults with kidney failure and predialysis hyperkalemia (predialysis serum potassium [sK<sup>+</sup>] concentration >5.4 mmol/L after the long interdialytic interval [LIDI] and >5.0 mmol/L after ≥1 short interdialytic interval) who were receiving hemodialysis 3 times weekly were randomized to placebo or SZC 5 g once daily on nondialysis days. Doses were titrated towards maintaining normokalemia for 4 weeks (titration period) in 5-g increments up to 15 g. Primary efficacy was the proportion of responders during the 4-week evaluation period following the titration period (ie, those with a predialysis sK<sup>+</sup> of 4.0-5.0 mmol/L for at least 3 of 4 hemodialysis visits following the LIDI) who did not require urgent rescue therapy.FINDINGS: Overall, 134 adults (mean [SD] age, 55 [11.3] years) were randomized to SZC or placebo (n = 67 each). There were significantly more responders with SZC (37.3%) versus placebo (10.4%; estimated odds ratio [OR] = 5.10; 95% CI, 1.90-15.12; P < 0.001). The probability of all predialysis sK<sup>+</sup> concentrations being 3.5 to 5.5 mmol/L was significantly higher with SZC versus placebo (estimated OR = 6.41; 95% CI, 2.71-15.12; P < 0.001). A greater proportion of patients achieved an sK<sup>+</sup> of 3.5 to 5.5 mmol/L on at least 3 of 4 LIDI visits during evaluation with SZC (73.1%) versus placebo (29.9%). Serious adverse events occurred in 9.1% and 11.9% of patients in the SZC and placebo groups, respectively.IMPLICATIONS: SZC treatment for predialysis hyperkalemia is effective and well tolerated in Chinese patients with kidney failure receiving hemodialysis.CLINICALTRIALS: gov identifier: NCT04217590.
pharmacology & pharmacy